These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17542008)

  • 1. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series.
    Spiridigliozzi GA; Heller JH; Crissman BG; Sullivan-Saarela JA; Eells R; Dawson D; Li J; Kishnani PS
    Am J Med Genet A; 2007 Jul; 143A(13):1408-13. PubMed ID: 17542008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17.
    Kishnani PS; Heller JH; Spiridigliozzi GA; Lott I; Escobar L; Richardson S; Zhang R; McRae T
    Am J Med Genet A; 2010 Dec; 152A(12):3028-35. PubMed ID: 21108390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
    Prasher VP; Huxley A; Haque MS;
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):270-8. PubMed ID: 11921156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.
    Heller JH; Spiridigliozzi GA; Sullivan JA; Doraiswamy PM; Krishnan RR; Kishnani PS
    Am J Med Genet A; 2003 Jan; 116A(2):111-6. PubMed ID: 12494428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of donepezil on cognitive functioning in Down syndrome.
    Johnson N; Fahey C; Chicoine B; Chong G; Gitelman D
    Am J Ment Retard; 2003 Nov; 108(6):367-72. PubMed ID: 14561111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures.
    Handen BL; Johnson CR; McAuliffe-Bellin S; Murray PJ; Hardan AY
    J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):43-50. PubMed ID: 21309696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil for Down's syndrome.
    Kishnani PS; Spiridigliozzi GA; Heller JH; Sullivan JA; Doraiswamy PM; Krishnan KR
    Am J Psychiatry; 2001 Jan; 158(1):143. PubMed ID: 11136652
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.
    Kishnani PS; Sommer BR; Handen BL; Seltzer B; Capone GT; Spiridigliozzi GA; Heller JH; Richardson S; McRae T
    Am J Med Genet A; 2009 Aug; 149A(8):1641-54. PubMed ID: 19606472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome and Alzheimer disease: response to donepezil.
    Lott IT; Osann K; Doran E; Nelson L
    Arch Neurol; 2002 Jul; 59(7):1133-6. PubMed ID: 12117361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
    Rogers SL; Friedhoff LT
    Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emergence of pharmacotherapies for cognitive function in Down syndrome.
    Capone GT
    Am J Med Genet A; 2010 Dec; 152A(12):3026-7. PubMed ID: 21108389
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
    Salloway S; Ferris S; Kluger A; Goldman R; Griesing T; Kumar D; Richardson S;
    Neurology; 2004 Aug; 63(4):651-7. PubMed ID: 15326237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
    Doody RS; Geldmacher DS; Gordon B; Perdomo CA; Pratt RD;
    Arch Neurol; 2001 Mar; 58(3):427-33. PubMed ID: 11255446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
    Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
    Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
    Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
    Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
    Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
    Black S; Román GC; Geldmacher DS; Salloway S; Hecker J; Burns A; Perdomo C; Kumar D; Pratt R;
    Stroke; 2003 Oct; 34(10):2323-30. PubMed ID: 12970516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study.
    Cubo E; Fernández Jaén A; Moreno C; Anaya B; González M; Kompoliti K
    Clin Ther; 2008 Jan; 30(1):182-9. PubMed ID: 18343255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.